Clinical trials: Elderly Lymphoma Patients
Lymphoma
Combination Chemotherapy Plus Filgrastim With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies such as rituximab can locate tumor cells and either kill them or deliver tumor-killing…
- Trial name
- NCT00028717
- Testing
- filgrastim, rituximab, cyclophosphamide
- Where
- 13 sites in Netherlands
- Volunteers
- 400 people
- Sponsor
- Commissie Voor Klinisch Toegepast Onderzoek
Hodgkin Lymphoma, Coexisting Medical Conditions
Study Of Nivolumab Alone, Or In Combination With Vinblastin In Patients With Classical Hodgkin Lymphoma
This study is a multicentric phase II open-label trial consisting of 6 cycles Nivolumab (2 weeks interval) followed by a PET-CT scan. The treatment will be allocated according to PET and CT scan responses.
- Trial name
- NCT03580408
- Testing
- Nivolumab, Vinblastin
- Where
- 51 sites in Belgium, France
- Volunteers
- 64 people
- Sponsor
- The Lymphoma Academic Research Organisation
Diffuse Large B-Cell Lymphoma
The Efficacy and Safety of ZR2 Versus R-miniCHOP in the Treatment of Unfit or Frail de Novo Diffuse Large B-cell Lymphoma Patients Aged Older Than or Equal to 70 Years
A multicenter, prospective, randomized, open-label, controlled trial to evaluate the efficacy and safety of zanubrutinib, rituximab and lenalidomide (ZR2) versus rituximab combined with low-dose CHOP (R-miniCHOP) in the treatment…
- Trial name
- NCT05179733
- Testing
- six courses of zanubrutinib, rituximab and lenalidomide, six courses of rituximab combined with low-dose CHOP
- Where
- China
- Volunteers
- 280 people
- Sponsor
- Ruijin Hospital
Lymphoma, Large-Cell, Diffuse
R-ICE Versus R-DHAP in Patients Aged 18-65 With Relapse Diffuse Large B-cell Lymphoma
The primary objective of this study is to evaluate the efficacy and safety of induction therapy R-ICE in comparison to R-DHAP after 3 cycles adjusted to successful mobilization of stem cells in patients with previously treated…
- Trial name
- NCT00137995
- Testing
- Rituximab, Etoposide, Carboplatine
- Where
- 10 sites in United States, Australia and 8 more
- Volunteers
- 481 people
- Sponsor
- Lymphoma Study Association
Non Hodgkin's Lymphoma
Adjuvant Low Dose Total Body Irradiation in Elderly Patients With Diffuse Large B-Cell Lymphoma
The purpose of this study is to determine whether the application of low dose total body irradiation following chemo-immuntherapy in elderly patients with aggressive with non-Hodgkin's lymphoma would be safe and potentially…
- Trial name
- NCT00834951
- Testing
- Low dose total body irradiation
- Volunteers
- 40 people
- Sponsor
- University of Aarhus
Leukemia, Lymphoblastic, Acute
Dasatinib and Low Intensity Chemotherapy for Ph+ Acute Lymphoblastic Leukemia
1. The use of imatinib in combination or in association with chemotherapy is now considered as the gold standard for the treatment of Ph+ ALL. The complete remission (CR) rate is 90% versus 20% to 40% with chemotherapy alone.
- Trial name
- EWALLPH01 (NCT02888990)
- Testing
- Dasatinib
- Where
- 64 sites in Belgium, France and 2 more
- Volunteers
- 71 people
- Sponsor
- Versailles Hospital
Acute Lymphoblastic Leukemia, Adult
Study in Adult Ph-positive ALL
An Open Label, 3-arm, Randomised Phase II Study to Compare the Safety and Efficacy of Ponatinib in Combination With Either Chemotherapy or Blinatumomab With Imatinib Plus Chemotherapy as Front-line Therapy for Patients Aged 55…
- Trial name
- EWALL-Ph-03 (NCT04688983)
- Testing
- Ponatinib, Blinatumomab, Imatinib
- Volunteers
- 180 people
- Sponsor
- Cardiff University
Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) in Elderly Patients With Untreated Follicular Non-Hodgkin's Lymphoma (NHL)
This study will evaluate the efficacy and safety of brief induction therapy with a chemotherapeutic regimen containing MabThera, followed by either maintenance therapy with MabThera or no further therapy.
- Trial name
- NCT01144364
- Testing
- rituximab [Mabthera/Rituxan]
- Where
- 45 sites in Italy
- Volunteers
- 234 people
- Sponsor
- Hoffmann-La Roche
Diffuse Large B Cell Lymphoma
Treatment of Elderly Patients With Diffuse Large B-cell Lymphoma
To explore the clinical features and efficacy evaluation of large b-cell lymphoma in old age.
- Trial name
- NCT03513601
- Testing
- (R)-CHOP regimen, (R)-CVP regimen
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Mingzhi Zhang
Diffuse Large B-cell Lymphoma
Rituximab Plus Bendamustine as Front Line Treatment in Frail Elderly (>70 Years) Patients With DLBCL: a Phase II Multicenter Study of the FIL
The purpose of the study is to evaluate feasibility and efficacy of rituximab-bendamustine (R-B)combination in elderly patients affected by diffuse large B-cell lymphoma and defined as frail according to CGA.
- Trial name
- NCT01990144
- Testing
- Bendamustine+Rituximab
- Where
- 52 sites in Italy
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Fondazione Italiana Linfomi - ETS
Lung Cancer, Gastro-intestinal Cancer
The SOAR Study: a Study of Geriatric Assessment and Exercise for Older Adults and Their Support Person
Phase 2 randomized controlled study using a waitlist control group. The study also has a single arm pre-post test 12-week chair-based exercise arm for those who have received the geriatric assessment in the older adults with…
- Conditions
- Lung Cancer, Gastro-intestinal Cancer, Genito-Urinary Cancer, Breast Cancer
- Trial name
- SOAR (NCT05509751)
- Testing
- GAM, exercise, health education, online chair-based exercise combined with health education
- Where
- 2 sites in Canada
- Volunteers
- 60 people
- Sponsor
- Martine Puts
Lymphoma
Assessing Antibody Responsiveness to Hepatitis B Vaccine in Aged Lymphoma Patients Undergoing Treatment With Rituximab
Background: The ability of the immune system to function declines with aging. This is reflected by a marked decrease in the responsiveness to vaccinations and to infectious agents.
- Trial name
- NCT00863187
- Testing
- rituximab
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Rambam Health Care Campus
Hodgkin Lymphoma
Immunological Senescence Phenotype as a Resistance Profile to Pembrolizumab in Patients With Relapsed/Refractory Hodgkin's Lymphoma
This is a single-centre, observational, prospective and exploratory study, which involves the use of human tissues from patients affected by Relapsed/Refractory classic Hodgkin Lymphoma treated with pembrolizumab at the…
- Trial name
- HL-SIP (NCT06733987)
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Lymphoma
Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies such as rituximab can locate tumor cells and either kill them or deliver tumor-killing…
- Trial name
- NCT00052936
- Testing
- filgrastim, rituximab, CHOP regimen
- Where
- 174 sites in Germany, Switzerland
- Volunteers
- 1,506 people
- Sponsor
- German High-Grade Non-Hodgkin's Lymphoma Study Group
Diffuse Large B-Cell Lymphoma
Study of Bendamustine and Ofatumumab in Elderly Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma Who Are Poor Candidates for R-CHOP Chemotherapy
This is a single-arm, Phase II study designed to enroll and treat up to 64 patients. All patients in this study will receive ofatumumab and bendamustine as an IV infusion for 6 cycles (a cycle is defined as 21 days in length).
- Trial name
- NCT01626352
- Testing
- Bendamustine, Ofatumumab
- Where
- 11 sites in United States
- Volunteers
- 22 people
- Sponsor
- SCRI Development Innovations, LLC
Hodgkin Lymphoma
Adriamycin, Vinblastine, DTIC and Revlimid in Elderly Hodgkin Lymphoma Patients
The purpose of this study is to determine within the scope of the trial what the maximum tolerated dose (MTD) of lenalidomide in combination with AVD should be.
- Trial name
- AVD-Rev (NCT01056679)
- Testing
- Doxorubicine, DTIC, Lenalidomide
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- University of Cologne
Diffuse Large B Cell Lymphoma
Study Evaluating the Safety and Efficacy of iR2 in Untreated and Unfit Elderly Patients With DLBCL
This is a single-arm, open-label phase 2 study of iR2 in the treatment of unfit and elderly patients with untreated diffuse large B-cell lymphoma。
- Trial name
- NCT03949062
- Testing
- Ibrutinib, Lenalidomide, Rituximab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Ruijin Hospital
Leukemia, Lymphoma
Resiliency in Older Adults Undergoing Bone Marrow Transplant
The objective of this research is to measure certain indicators of resiliency to better understand which participants who are over 60 years old will respond more positively to bone marrow transplant.
- Conditions
- Leukemia, Lymphoma, Blood Cancer, Myelodysplastic Syndrome
- Trial name
- REBOUND (NCT04188678)
- Testing
- Bone Marrow Transplant (BMT)
- Where
- United States
- Volunteers
- 126 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
COVID-19
The Standard of Care Combined With Glucocorticoid in Elderly People With Mild or Moderate COVID-19
This study is aimed to explore the dual-dimensional early intervention strategy of standard of care combined with host immunomodulation in elderly patients with mild and moderate COVID-19.
- Trial name
- NCT05855395
- Testing
- Glucocorticoid
- Where
- 15 sites in China
- Volunteers
- 5,815 people
- Sponsor
- Huashan Hospital
Lymphoblastic Leukemia, Acute
Tyrosine Kinase Inhibitors and Low Intensity Chemotherapy in Ph+ ALL
The use of imatinib in combination with chemotherapy is now considered as the gold standard for the treatment of Ph+ ALL. The complete remission (CR) rate is 90% versus 20% to 40% with chemotherapy alone.
- Trial name
- EWALL_OBS (NCT02888977)
- Where
- 3 sites in France
- Volunteers
- 100 people
- Sponsor
- Versailles Hospital